UNITED STATES PATENT APPLICATION

By

James M. Lipton

For

METHODS AND COMPOUNDS FOR TREATING MALABSORPTION DISEASES AND INFLAMMATORY CONDITIONS OF THE GASTROINTESTINAL TRACT

PRIORITY CLAIM

[0001]   This application claims priority to U.S. Provisional Application Serial No. 60/445,542, filed on February 6, 2003, and is incorporated by reference as if fully set forth herein, including drawings.

FIELD OF THE INVENTION

[0002]   The present invention relates to the field of prevention and treatment of malabsorption and inflammatory conditions of the intestines.

BACKGROUND OF THE INVENTION

[0003]   The gastrointestinal tract ("GIT") digests and absorb nutrients including macromolecules required for energy or micronutrients such as trace elements and vitamins. The absorptive function of the GIT ranges from the μg level to kg level. For example 1 μg of vitamin B_{12} may be absorbed daily with respect to a highly specific and complex process in the terminal ileum. Conversely, the GIT may digest, solubilize, transport and resynthesize 0.8 kg of fat daily.

[0004]   Beyond the net absorption of dietary components, the GIT has a large daily internal circulation of water, electrolytes and bile salts that are secreted in gastric juice, pancreatic juice, bile and succus entericus and then reabsorbed in the small intestine (duodenum-jejunum-ileum) and colon (cecum-ascending-transverse-descending-sigmoid-rectum). Andreoli, Carpenter, Plum Smith, *Cecil Essentials of Medicine* pp.267-270, (W.B. Saunders Co. 1986). The GIT must first prepare for the later absorption of the basic mixtures of nutrients and non-nutrients ingested as bolus, or food. The preparatory processes of digestion consist, basically, of the controlled release into the intestine of food that has been fragmented to small particle size by the grinding action of the stomach; the release of the appropriate amount of enzymes, cofactors, bicarbonate, detergents and water into the lumen; and further digestion of food to disaccharides and oligopeptides by brush border bound enzymes. Absorption follows at various levels of the duodenum, jejunum and ileum. *Id.*

[0005]   The surface area available to the GIT is enormous. The overall length of the small intestine is minimal compared to the surface area which, in a normal adult human, is about the area of a tennis court. This added surface area is supplied by the intestinal villi and microvilli.

[0006]   Absorption is a highly complex and coordinated process and in view of the many complexities is vulnerable to a large number of disorders that result in maldigestion or malabsorption. These many disorders may act specifically at the site of insult or more globally. The primary focus of the present invention is the malabsorptive diseases.

[0007]   Many disorders of the GIT can be listed in the category of malabsorption.

This list includes, but is not limited to, celiac sprue (gluten-sensitive enteropathy),

Crohn's disease, abetalipoproteinemia, Hartnup's disease, tropical sprue, bacterial

overgrowth syndrome, cystinuria, monosaccharide absorptive defects, Whipple's disease

5   and infective, immunologic or allergic injury. These disorders vary from specific genetic

defects to the acquired diffuse mucosal diseases and represent a broad spectrum of

conditions with varying etiologies. Clinical manifestations are equally diverse. *Id.*

[0008]   Treatments of the various malabsorption diseases, for the most part, match

the disease entity. For example, bacterial overgrowth is battled with antibiotics, as is

10   Whipple's disease. Celiac sprue, on the other hand, is treated with a gluten free diet.

Most treatments are symptomatic as opposed to prophylactic. Patients with chronic

malabsorption diseases would benefit from a treatment that both addressed prevention

and maintenance.

[0009]   This is especially true in celiac disease, or gluten-sensitive enteropathy.

15   This disease is a familiar, chronic familial disorder associated with a life-long sensitivity

to dietary gluten, or more specifically, gliadin (a component of gluten). The disease is

especially significant in that gluten is a predominant protein found in wheat and wheat

products, barley, rice and, in smaller amounts, oats. When gluten is ingested by a person

with gluten-sensitivity, a diffuse mucosal injury results that is characteristic of the

20   disease, but in no way specific. Histologically, the villi are shortened and blunted in one

with celiac disease. The blunted and shortened villi result in a less absorptive surface

area. The crypts, the areas between the villi, are hyperplastic and the lamina propria, the layer of connective tissue underlying the epithelium of a mucous membrane, is usually heavily infiltrated with lymphocytes. Ferguson A, Murray D., *Quantitation of intraepithelial lymphocytes in human jejunum*, Gut 1971; 12:988-994.

5   **[0010]**   Pathogenically, the etiology has yet to be fully established. Evidence suggests an immunological mechanism. Andreoli, Carpenter, Plum Smith, *Cecil Essentials of Medicine* pp. 267-270, (W.B. Saunders Co. 1986). Environmental and genetic causes are also important. Braunwald, Fauci, Kasper, Longo, Jameson *Harrison's Principles of Internal Medicine*, pp. 1165-1674, (15th Ed. McGraw Hill, 2001). Patients

10 with a celiac sprue have a high prevalence for the histocompatibility types HLA-B8 and Dw3. This suggests a linkage on chromosome 6 and strengthens the possibility that the disease may be of immunological origin. Regardless of the origin, however, it is known that the lesions connected with celiac sprue are locally produced. *Id.*

[0011]   The local lesions of celiac sprue occur mostly in the duodenal-proximal

15 jejunal mucosa. The most important complication of celiac disease is the development of a malignancy. There is an increased incidence of both gastrointestinal and nongastrointestinal neoplasms as well as lymphoma in patients with celiac disease. *Id.* Ulceration is another complication of celiac disease. Because celiac disease is a multifactorial disease and exhibits, among other complications, both nutritional and

20 inflammatory complications, a treatment that responds to the multifactorial nature of the disease is needed. The same is true for the malabsorption diseases in general.

[0012]   The specific categorization of celiac disease is a disorder characterized by

intolerance to gluten, malabsorption, and abnormal small bowel structure. Schuppan D,

Current concepts of celiac disease pathogenesis, Gastroenterology 2000; 119:234-242.

The disease is believed to be caused by a T cell-mediated hypersensitivity reaction to

5   certain A-gliadin polypeptides in genetically susceptible patients. The small intestinal

mucosa of affected patients shows crypt cell hyperplasia and villous flattening, which are

the pathognomonic lesions of the disease. Paulley LW, *Observations on the aetiology of*

idiopathic steatorrhoea, Br Med J 1954; 2:1318-1321; Yardley JH, Bayless TM, Norton

JH, Hendrix TR., *Celiac disease: a study of the jejunal epithelium before and after a*

10   *gluten free diet,* New Engl J Med 1962; 267:1173-1179. The lamina propria is infiltrated

with lymphocytes, macrophages, and plasma cells. Inflammatory mediators released by

infiltrating cells likely contribute to development of the disease. Ferguson A, MacDonald

TT, McClure JP, Holden RJ, *Cell-mediated immunity to gliadin within the small-*

intestinal mucosa in coeliac disease, Lancet 1975; 1:895-897. Immunohistochemical

15   analysis of celiac mucosa showed increased number of cells positive for interferon γ

(IFN-γ) in the lamina propria (Nilsen EM, Jahnsen FL, Lundin KE, Johansen FE, Fausa

O, Sollid LM, Jahnsen J, Scott H, Brandtzaeg P., *Gluten induces an intestinal cytokine*

response strongly dominated by interferon gamma in patients with celiac disease,

Gastroenterology 1998; 115:551-563) and for interleukin 6 (IL-6) and tumor necrosis

20   factor α (TNF-α) both in the lamina propria and epithelium. Przemioslo RT, Kontakou

M, Nobili V, Ciclitira PJ, *Raised pro-inflammatory cytokines interleukin 6 and tumor*

necrosis factor a in coeliac disease mucosa detected by immunohistochemistry, Gut 1994;

35:1398-1403. Further, gliadin stimulation of duodenal specimens *in vitro* elicited

expression of the pro-inflammatory cytokines, including IFN-γ, IL-6 and TNF-α. Nilsen

EM, Jahnsen FL, Lundin KE, Johansen FE, Fausa O, Sollid LM, Jahnsen J, Scott H,

5   Brandtzaeg P., *Gluten induces an intestinal cytokine response strongly dominated by*

interferon gamma in patients with celiac disease, Gastroenterology 1998; 115:551-563;

Beckett CG, Dell'Olio D, Shidrawi RG, Rosen-Bronson S, Ciclitira PJ., *Gluten-induced*

nitric oxide and pro-inflammatory cytokine release by cultured celiac small intestinal

biopsies, Eur J Gastroenterol Hepatol 1999; 11:529-535.

10   **[0013]**   Currently, treatment is directed to removing the source of gliadin from the

diet. Thus, once lesions have been created in the intestinal tract, they remain inflamed

and painful until there is healing via the body's reparative system. Unfortunately, lesions

may progress before the body has healed them. These lesions may progress on to chronic

ulceration or to malignancy. The most common medications used to treat inflammation

15   Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are most often contraindicated in

patients with any type of history of gastritis, or history of ulcer. Steroids, a more

aggressive anti-inflammatory treatment, pose the additional risks, including that an ulcer

may become infected but go unnoticed due to the well-known side effect of systemic

steroids in masking infections. A treatment is needed that is natural and does not interfere

20   with the body's natural defense mechanisms. Such a treatment compound and method is

disclosed in this invention.

SUMMARY OF THE INVENTION

[0014]   The current invention is directed to treatment of malabsorption diseases and inflammatory disorders of the GIT using a combination of artichoke leaf extract and the peptide, α-melanocyte stimulating hormone. Alpha-melanocyte stimulating hormone ("α-MSH") has potent anti-inflammatory activity and artichoke leaf extract is known for its anti-cholesterol anti-gastritis effects. Recent research by the inventors has shown that α-MSH and its receptors participate in the anti-inflammatory response in the duodenal mucosa of celiac patients. The same is contemplated for derivatives of α-MSH. α-MSH and/or its derivatives may be used in medicinal preparations to treat and help prevent the complications associated with celiac disease and other inflammatory conditions of the GIT.

[0015]   The presence of α-MSH and its receptors in celiac mucosa suggests the presence of a local reaction to control the inflammatory response elicited by gliadin. The inhibitory effects of synthetic α-MSH on mucosal IL-6 production is consistent with such a local modulatory reaction based on the peptide. This local action may be beneficially controlled or modified with medicinal administration of α-MSH and/or its derivatives. In this respect, the invention may be used as a preventive measure as well as a treatment during an attack. Further, it has been shown that artichoke leaf extract reduces symptoms of irritable bowel syndrome.

[0016]   It is contemplated that artichoke leaf extract and α-MSH and/or its derivatives will be administered via oral, anal, mucosal or paranteral routes. Accordingly,

artichoke leaf extract and α-MSH and/or its derivatives will be administered using tablets,

capsules, powders, suppositories, aerosolized sprays and injectables.

DESCRIPTION OF FIGURES

[0017]   Fig. 1. α-MSH release by duodenal mucosa specimens incubated for 24 h *in*

vitro. Open bars denote incubation in medium alone; black bars represent incubation in

medium + gliadin. Spontaneous α-MSH production was significantly greater in untreated

celiac patients relative to both control subjects and treated celiac patients. Co-incubation

of mucosa specimens with gliadin elicited further release of α-MSH only in untreated

celiac patients. (In this and following figures bars represent mean f SE).

[0018]   * p<0.05: spontaneous release in celiac patients vs. controls and treated

celiac patients, and gliadin stimulated vs. spontaneous release in celiac patients.

[0019]   Fig. 2. Immunohistochemical detection of α-MSH in a duodenal specimen

from a patient with untreated celiac disease. (Original magnification X220).

[0020]   Fig. 3. Agarose gel electrophoresis of representative RT-PCR amplified

mRNA for POMC and MCIR in duodenal specimens from: a normal subject (1st lane), an

untreated celiac patient (2nd lane), and a treated celiac patient (3rd lane). X174 RF

DNAIHae III fragments were used as molecular weight markers (4th lane). A) POMC

mRNA 260 by amplified fragment. B) MClR mRNA 416 by amplified fragment. C)

G3PDH mRNA 980 by amplified fragment. The indicated size (base pairs) of the

amplification products matched that predicted from the position of the primer pairs.

[0021]   Fig. 4. Immunohistochemical detection of MCIR in normal duodenal

mucosa and in duodenal specimens from two patients with celiac disease. Arrows denote

immunoreactive cells. A) Normal villi with no MCIR immunoreactive cells on the

villous surface. B) Specimen from the same subject showing goblet cells of glands

5   weakly stained with the anti-MCIR antibody. C) MCIR immunoreactive cells on the

surface of flattened villi in a patient with untreated celiac disease. D) Specimen from the

same subject showing intense MCIR immunoreactivity of goblet cells. E) and F)

Duodenal mucosa specimens from a celiac patient treated with an embodiment of the

invention. Relative to the untreated patient, immunoreactive cells are fewer and intensity

10   of staining is lower. However, distribution of positive cells is similar to that of the

untreated patients, involving the villous surface. (Original magnification x 110).

[0022]   Fig. 5. Immunohistochemical detection of MC5R in duodenal specimens

from: A) normal subject, B) patient with untreated celiac disease, and C) treated celiac

patient. Scattered cells were marked with the antiserum against MC5R; there were no

15   substantial differences among normal, celiac, or celiac subjects treated with an

embodiment of the invention. (Original magnification x220).

[0023]   Fig. 6. Effect of gliadin on IL-6 production by duodenal specimens

incubated for 24 h *in vitro* (open bars), and influence of α-MSH on such production

(black bars). IL-6 production was markedly enhanced in untreated celiac patients,

20   although a small increase occurred also in the other two groups. Coincubation of gliadin-

stimulated duodenal specimens with α-MSH (10-5 M) significantly decreased IL-6

production.

[0024]   (* $p < 0.05$; ** $p < 0.01$)

DETAILED DESCRIPTION OF THE INVENTION

5   **[0025]**   All references cited are fully incorporated as if fully set forth herein.

Research by the inventors, discussed more fully below, has shown that human duodenal

mucosa is a source of α-MSH and that the duodenal mucosa expresses melanocortin

receptors. Both production of α-MSH and MC1R immunoreactivity, were considerably

enhanced in duodenal samples from untreated celiac patients. That observation suggested

10   that locally produced α-MSH, a potent anti-inflammatory agent, could modulate

inflammation and possibly reduce epithelial damage. When gliadin-stimulated celiac

mucosa was incubated with synthetic α-MSH there was a substantial reduction in IL-6

production. Thus, it is contemplated that the invention may be used as a therapeutic

measure before, during and after the complications of a malabsorption condition have

15   arisen.

[0026]   Although understanding of the mechanism of anti-inflammatory action of α-

MSH is incomplete, part of its anti-inflammatory influence is exerted through reduced

production of inflammatory mediators by host cells. α-MSH inhibits the inflammatory

cascade at many sites: it reduces production of NO (Star RA, Rajora N, Huang J, Stock

20   RC, Catania A, Lipton JM., *Evidence of autocrine modulation of macrophage nitric oxide*

synthase by alpha-melanocyte-stimulating hormone, Proc Natl Acad Sci USA 1995;

92:8016-8020), proinflammatory cytokines (Lipton JM, Catania A., *Anti-inflammatory*

actions of the neuroimmunomodulator α-MSH, Immunol Today 1997; 18:140-145),

monocyte chemoattractant protein 1 (MCP-1), and interleukin 8 (IL-8), and markedly

decreases neutrophil chemotaxis *in vivo* and *in vitro*. Mason MJ, Van Epps D.,

5   *Modulation of IL-l, tumor necrosis factor, and C5a-mediated murine neutrophil*

migration by a-melanocyte-stimulating hormone. J Immunol 1989; 142:1646-1651;

Catania A, Rajora N, Capsom F, Minonzio F, Star RA, Lipton JM, *The neuropeptide α-*

MSH has specific receptors on neutrophils and reduces chemotaxis in vitro, Peptides

1996; 17:675-679. These effects of the peptide are exerted, at least in part, through

10   inhibition of activation of the nuclear factor NF-κB, a pivotal transcription factor for

genes that encode proinflammatory cytokines, chemokines, and adhesion molecules.

Manna SK, Aggarwal BB, *α-Melanocyte-stimulating hormone inhibits the nuclear*

transcription factor NT-KB activation induced by various inflammatory agents, J

Immunol 1998; 161:2873-2880; Ichiyama T, Zhao H, Catania A, Furukawa S, Lipton JM,

15   *α-Melanocyte-stimulating hormone inhibits NF-KB activation and IKBa degradation in*

human glioma cells and in experimental brain inflammation, Exp Neurol 1999; 157:359-

365.

[0027]   It is known that the influences of melanocortin peptides, including α-MSH,

are mediated through activation of melanocortin receptors (MCRs). The cloning and

20   characterization of the MCR genes (MC1R through MC5R) have led to a great

advancement in understanding the biological effects of melanocortins. Abdel-Malek ZA,

Melanocortin receptors: their functions and regulation by physiological agonists and antagonists, Cell Mol Life Sci 2001; 58:434-441. Each receptor is the product of a separate gene and collectively they represent a distinct family of seven transmembrane domain G-protein coupled receptors. Activation of the MCRs by binding of their specific

5   agonists results in stimulation of cAMP formation. Although the function of each MCR is not completely known, it is clear that these receptors have different affinities for the individual melanocortin peptides and mediate separate effects. Virtually all cells involved in inflammatory responses express one or more subtypes of melanocortin receptors.

10   **[0028]**   Human monocyte/macrophages express MC1R, the receptor with the highest affinity for α-MSH (Taherzadeh S, Sharma S, Chhajlani V, Gantz I, Rajora N, Demitri MT, Kelly L, Zhao H, Catania A, Lipton JM, *α-MSH and its receptors in regulation of inflammatory tumor necrosis factor-a (TNF-α) by human monocyte/macrophages*, Am J Physiol 1999; 276:R1289-R1294), which is also expressed

15   by human neutrophils (Catania A, Rajora N, Capsom F, Minonzio F, Star RA, Lipton JM, *The neuropeptide α-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro*, Peptides 1996; 17:675-679), and endothelial cells. Abdel-Malek ZA, *Melanocortin receptors: their functions and regulation by physiological agonists and antagonists*, Cell Mol Life Sci 2001; 58:434-441. MC3R and MC5R expression has also been found in

20   human monocytes.

[0029]   The current invention is based on findings by the inventors of the occurrence of an anti-inflammatory circuit based on α-MSH and its receptors in celiac mucosa. Locally produced and/or circulating α-MSH can exert anti-inflammatory influences through binding to MC1R receptors. Several data support this idea: a) celiac

5   mucosa specimens incubated *in vitro* produce greater concentrations of α-MSH, both spontaneously and after gliadin stimulation; b) MC1R, the receptors with the greatest affinity for α-MSH are hyperexpressed in untreated celiac patients; c) IL-6 production is inhibited by addition of α-MSH to culture medium.

[0030]   Anti-inflammatory circuits based on α-MSH and its receptor(s) are probably

10   widespread in tissues. Functionally equivalent derivatives of α-MSH may react within these same circuits. Previous research indicated the existence of an autocrine loop in human macrophages: such cells produce α-MSH and express the MC1R; immunoneutralization of MCIR enhances production of TNF. Local production of α-MSH likewise occurs in synovium of rheumatoid arthritis patients. Catania A, Gerloni V,

15   Procaccia S, Airaghi L, Manfredi MG, Lomater C, Grossi L, Lipton JM, *The neuropeptide α-MSH in synovial fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules*, Neuroimmunomodulation 1994; 1:321-328.

[0031]   Inflammatory reactions in body tissues are modulated by endogenous molecules that reduce production of inflammatory mediators and limit tissue damage.

20   Therefore, the extent of tissue injury depends upon the amount of inflammatory products released and the effectiveness of general and local anti-inflammatory reactions. The data

relied on here suggest that α-MSH and its receptors contribute to the anti-inflammatory

reaction in celiac mucosa. In selected cases of refractory celiac disease or when

compliance to the gluten free diet is poor, treatment with exogenous peptides might be

considered. In this regard, previous research showing that α-MSH is highly effective in

5   preclinical treatment of inflammatory bowel disease (Rajora N; Boccoli G, Catania A,

Lipton JM., *α-MSH modulates experimental inflammatory bowel disease*, Peptides 1997;

18:381-385; Oktar BK, Ercan F, Yegen BC, Alican I, *The effect of a-melanocyte*

stimulating hormone on colonic inflammation in the rat, Peptides 2000; 21:1271-1277) is

particularly encouraging.

10   **[0032]**   Although the inflammatory component in celiac disease is well

characterized, there is less information about endogenous molecules that reduce such

inflammation. α-MSH is an established component in the host anti-inflammatory

reactions. Catania A, Lipton JM, *α-Melanocyte stimulating hormone in the modulation of*

host reactions. Endocr Rev 1993; 14:564-576; Catania A, Airaghi L, Colombo G, Lipton

15   JM, *α-MSH in normal human physiology and disease states*, Trends Endocrinol Metab

2000; 11:304-308. This molecule, produced by post-translational processing of pro-

opiomelanocortin (POMC), is a 13 amino acid peptide highly conserved across phylogeny

and widely expressed in tissues. Eberle AN, *The Melanotropins*, Basel (ed. S. Karger)

1988. The peptide is produced by the pituitary and by many extrapituitary cells,

20   including monocytes, astrocytes, gastrointestinal cells, and keratinocytes. Endogenous α-

MSH modulates fever and inflammation. Given in pharmacological concentrations, α-

MSH is extremely effective in preclinical treatment of local and systemic inflammatory

disorders including inflammatory bowel disease, sepsis syndrome, and rheumatoid

arthritis. Lipton JM, Ceriani G, Macaluso A, McCoy D, Carries K, Biltz J, Catania A,

Anti-inflammatory effects of the neuropeptide alpha-MSH in acute, chronic, and systemic

5   *inflammation*, Ann N Y Acad Sci 1994; 741:137-148; Lipton JM, Catania A, *Anti-*

inflammatory actions of the neuroimmunomodulator α-MSH, Immunol Today 1997;

18:140-145.

[0033]   Although plasma concentrations of α-MSH increase in certain infectious or

inflammatory disorders, (Catania A, Airaghi L, Colombo G, Lipton JM, *α-MSH in normal*

10   *human physiology and disease states*, Trends Endocrinol Metab 2000; 11:304-308;

Lipton JM, Catania A, *Anti-inflammatory actions of the neuroimmunomodulator α-MSH*,

Immunol Today 1997; 18:140-145) and there is evidence of descending modulatory

reactions stemming from MSH peptide receptors within the brain (Macaluso A, McCoy

D, Ceriani G, Watanabe T, Biltz J, Catania A, Lipton JM, *Anti- inflammatory influences*

15   *of α-MSH molecules: central neurogenic and peripheral actions*, J Neurosci 1994;

14:2377-2382), it is clear that the peptide produced at the site of an inflammatory process

can exert its effects locally, in the absence of any significant change in circulating

peptide. Synovial production of α-MSH in rheumatoid arthritis patients provides a good

example of such local influences. Catania A, Gerloni V, Procaccia S, Airaghi L,

20   Manfredi MG, Lomater C, Grossi L, Lipton JM, *The neuropeptide α-MSH in synovial*

fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules.

Neuroimmunomodulation 1994; 1:321-328.

[0034]   It is contemplated that derivatives of α-MSH will have analogous function.

It is understood that derivatives of α-MSH means functionally equivalent peptides. For

5   example, certain segments of α-MSH are known to have more potent anti-inflammatory

and/or antipyretic properties. Thus, α-MSH derivative would include, among others, the

partial segments of the 13 amino acid peptide. Specifically, α-MSH is composed of the

following sequence of amino acids: SYSMEHFRWGKPV (SEQ ID. NO. 1). Thus, KPV

(SEQ ID. NO. 2), which has been shown to be as potent or more potent than the parent α-

10   MSH, is a functional equivalent. Further, similar efficacies, when compared to α-MSH,

have been shown for MEHFRWGKPV (SEQ ID. NO. 3), HFRWFKPV (SEQ ID. NO. 4)

and, as mentioned, KPV (SEQ ID. NO. 2). These derivatives of the parent α-MSH are

functional equivalents. Inventors have also discovered that the sequence His-DNle-Arg-

Trp-Phe-Lys-Pro-Val (SEQ. ID NO. 5) has increased potency over the parent α-MSH and

15   its derivatives.

[0035]   Further, it is understood that α-MSH and/or its derivatives may be used in

this invention as a dimer. For example, the dimer of KPV is VPK-Ac-CC-Ac-KPV (SEQ

ID. NO. 6). Moreover, it is known that substitution of certain amino acids with their

stereo isomer results in a molecule with similar or greater efficacy. Thus, KDPV, where

DP is the D-isomer of proline, is an effective functional equivalent of α-MSH.

Substitutions with other equivalent amino acids may also be employed. For example, by

substitutions at amino acid 4 and 7 in the α-MSH parent molecule, the resulting molecule

becoming [Nle^4,D-Phe^7]- α-MSH ("NDP-α-MSH"), has been shown be a stable and

5   potent functional equivalent of α-MSH. This is further described in Example 1, below.

[0036]   Efficacy and duration of action of peptides may be additionally improved

through protection of the functional groups of the peptides. This is a process well known

and understood in the art. It is contemplated that the peptides of this invention will be

protected by esterification or amidation of the –COOH to –COO-alkyl or –CONH$_2$. The

10   preferred alkyl groups for the carboxy terminus include methyl and benzyl residues, yet

other alkyl groups, such as ethyl, propyl, butyl, p-nitrobenzyl or p-methoxybenzyl groups

can be used.

[0037]   Likewise, the amino terminus is protected by acylation via introduction of a

carboxyl group such as an acetyl group, t-butyloxycarbonyl group, t-amyloxycarbonyl

15   group, p-nitrobenzyloxycarbonyl group, toysl or formyl group. Such amidation,

esterification, and acylation are disclosed in U.S. Patent No. 5,028,592 to Lipton.

[0038]   In one embodiment of the invention, α-MSH, and/or its derivatives, may be

administered parenterally. For this embodiment, pharmaceutical preparations of the

tripeptide, or its derivatives, may be generally obtained by combining the active

ingredient in combination with pharmaceutically acceptable buffers, dilutents, stabilizers, and the like. In a preferred composition, approximately 100 to 500mg of the active ingredient is dispersed into about 1-7ml of sterile, isotonic saline, including a pharmacologically accepted buffer to maintain pH at about neutral. Parenteral

5   administration may be desired when a GIT disease manifests pronounced stetorrhea, diarrhea or nausea/vomiting.

[0039]   Due to its small size, membrane permeability and relatively acid-stable structure, it will be recognized that the α-MSH, and/or its derivatives, may be administered orally, through the oropharanx or nasopharanx via an appropriate inhalant

10   apparatus or anally with the use of a suppository. For GIT disease or disorders, an oral route of administration is preferred.

[0040]   Pharmacologically effective concentrations of these peptides may be incorporated into commercial formulations of parenterals, tablets, capsules, powders for mixing with water, or atomized sprays. See, in general *Remington's Pharmaceutical*

15   *Sciences* (Mack Publishing Co., 18th ed. 1990).

[0041]   In one aspect of this invention a combination of artichoke leaf extract with α-MSH and/or its derivatives is contemplated. Artichokes, or *Cynara scolymus*, contain the active ingredient cynarin. Walker AF, Middleton RW, Petrowicz O. Cynarin is the active ingredient in artichoke leaf extract. Artichoke leaf extract and the products thereof

are found in most natural food and vitamin stores. The Hugh Sinclair Unit of Human

Nutrition, School of Food BioSciences, University of Reading, UK.

<food@afnovell.reading.ac.uk> It has been shown that cynarin is a natural therapeutic

helpful in the treatment of abdominal problems, irritable bowel syndrome, for example.

5   [0042]   Irritable bowel syndrome (IBS) is a problem reported to affect 22% of the

general population. IBS is characterized by abdominal pain and altered bowel habit but

has so far defied elucidation of its pathogenesis and proved difficult to treat. There is a

growing body of evidence that indicates therapeutic properties for artichoke leaf extract

(ALE). Dyspepsia and elevated cholesterol are the conditions for which the herb is

10   specifically indicated. Many symptoms overlap between dyspeptic syndrome and IBS

and this has given rise to the notion that ALE may have potential for treating IBS.

[0043]   In 1996 a German study using 553 patients with digestive disorders was

performed using ALE. Patients were given one or two 320mg capsules of ALE three

times a day for six weeks. As many as 80% of those studied reported overall relief.

15   Kennedy, J. Natural Health, 2002.

<http://www.atlantisherbs.com/Articles/artichokeIBS.htm>. Studies using ALE have

been performed that are specific to IBS and have shown an average improvement of

symptoms of 70%. Analysis of the data from the IBS study revealed significant

reductions in the severity of symptoms and favorable evaluations of overall effectiveness

20   by both physicians and patients. Furthermore most patients studied rated ALE as better

than or at least equal to previous therapies administered for their symptoms, and the

tolerability of ALE was very good. These results provide support for the notion that ALE

has potential value in relieving IBS symptoms and may be further enhanced used in

combination of α-MSH and or its derivatives. The combination of ALE and His-DNle-

5   Arg-Trp-Phe-Lys-Pro-Val (SEQ. ID NO. 5) may be the most potent.

[0044]   Set forth below are examples of various formulations of the invention. As

used below, the term "Active Ingredient" refers to α-MSH and/or its derivatives. In this

application, the term derivatives means those derivative discussed in Example 1 below as

well as any fragments of α-MSH or dimers of α-MSH or dimers of the fragments, thereof.

10   Dosages given in mg for the active ingredient are contemplated to be dosed at an average

of 1mg/kg of body weight for the individual to be treated. Thus, a 75kg person would be

given 75mgs of the active ingredient. Preferably, the active ingredient is KPV (SEQ ID.

NO. 1) or VPK-Ac-CC-Ac-KPV (SEQ ID. NO. 5).

[0045]   An exemplary parenteral preparation comprises:

Sterile Isotonic Saline	1-7cc
Pharmaceutically Accepted Buffer	In an amount adequate to maintain pH of about neutral
Artichoke Leaf Extract	320-1000mg
Active Ingredient	10-100mg

15   [0046]   An exemplary formulation of a hard gelatinous tablet comprises:

Gelatine Bloom 30	70.0mg
Maltodextrin MD 05	108.0mg
di-α-tocopherol	2.0mg

Sodium ascorbate	10.0mg
Microcrystalline cellulose	48.0mg
Artichoke Leaf Extract	320-1000mg
Magnesium stearate	2.0 mg
Active Ingredient	25.0 mg

[0047]   An exemplary formulation of a hard tablet with α-MSH and/or its

derivatives in combination with ALE comprises:

Anhydrous lactose	130.5mg
Microcrystalline cellulose	80.0mg
di-α-tocopherol	2.0mg
Sodium ascorbate	10.0mg
Polyvinylpyrrolidone K30	5.0mg
Artichoke Leaf Extract	320-1000mg
Magnesium stearate	2.0mg
Active Ingredient	25.0mg

Example I: KPV Derivatives

5   [0048]   This example illustrates the biological functional equivalents for, α-MSH;

termed herein as its derivatives. Although the specific amino acid sequence described

here is effective, it is clear to those familiar with the art that amino acids can be

substituted or deleted without altering the effectiveness of the peptides. Further, it is

known that stabilization of the α-MSH and /or its derivatives' sequence can greatly

10   increase the activity of the peptide and that substitution of D-amino acid forms for L-

forms can improve or decrease the effectiveness of the peptides. For example, a stable

analog of α-MSH, [Nle^4,D-Phe^7]- α-MSH, which is known to have marked biological

activity on melanocytes and melanoma cells, is approximately ten times more potent than

the parent peptide in reducing fever. Further, adding amino acids to the C-terminal of α-

MSH(11-13) (SEQ. ID. NO. 2) sequence can reduce or enhance antipyretic potency. It is

known that Ac-[D-K11]- α-MSH 11-13-NH2 has the same general potency as the L-form

of the tripeptide α-MSH (11-13) (SEQ. ID. NO. 2). However, substitution with D-proline

5   in position 12 of the tripeptide rendered it inactive. See e.g. Holdeman, M., et. al.,

Antipyretic Activity of a Potent α-MSH Analog, Peptides 6, 273-5 (1985). Deeter, L.B.,

et. al., *Antipyretic Properties of Centrally Administered α-MSH Fragments in the Rabbit,*

Peptides 9, 1285-8 (1989). Hiltz, M.E., *Anti-inflammatory Activity of α-MSH (11-13)*

Analogs: Influences of Alterations in Stereochemistry, Peptides 12, 767-71 (1991).

10   **[0049]**   Biological functional equivalents can also be obtained by substitution of

amino acids having similar hydropathic values. Thus, for example, isoleucine and

leucine, which have a hydropathic index +4.5 and+3.8, respectively, can be substituted

for valine, which has a hydropathic index of +4.2, and still obtain a protein having like

biological activity. Alternatively, at the other end of the scale, lysine (-3.9) can be

15   substituted for arginine (-4.5), and so on. In general, it is believed that amino acids can

be successfully substituted where such amino acid has a hydropathic score of within

about +/- 1 hydropathic index unit of the replaced amino acid. See, U.S. Patent No. 5,

157,023 issued to James M. Lipton issued on October 20, 1992.

Example 2: Use of α-MSH in Selected Sections of Intestinal Mucosa

[0050]   Three sets of experiments were performed using duodenal biopsy pairs from

53 adult celiac patients and 14 normal subjects to determine: 1. a) mucosal

immunoreactivity for (α-MSH and melanocortin receptors (MCRs); and b) gene

expression of α-MSH precursor pro-opiomelanocortin (POMC) and MCRs; 2. a) α-MSH

and cytokine production by duodenal specimens *in vitro*, and b) influence of synthetic α-

MSH on cytokine production; and 3. a) influence of stimulation with gliadin, the

subfraction of gluten that is toxic to patients with celiac disease, on α-MSH and cytokine

production *in vitro*, and b) effect of α-MSH on gliadin-stimulated cytokine production.

[0051]   Duodenal mucosa showed immunostaining for α-MSH, MC1R and MC5R.

α-MSH and MC1R immunoreactivity were more intense in specimens from celiac

patients. Specific mRNAs were likewise expressed. In experiments *in vitro*, synthetic α-

MSH significantly reduced interleukin 6 (IL-6) release in supernatants of gliadin-

stimulated duodenal mucosa.

[0052]   The inventors postulated that an autocrine anti-inflammatory circuit based

on α-MSH and its receptor(s) may occur in the celiac mucosa. To test this hypothesis, the

inventors determined generation and actions of α-MSH in specimens of duodenal mucosa

obtained from celiac patients. Because any effect of the peptide would be mediated by

binding to its receptor(s), we determined expression of subtypes of the known

melanocortin receptors (MCR). As an appraisal of the local anti-inflammatory influences

of α-MSH in celiac mucosa, we determined effects of incubation of intestinal mucosa

with the synthetic peptide on spontaneous and gliadin-induced cytokine production *in vitro*. The research plan included three separate sets of experiments performed on duodenal biopsy pairs from the same individual - celiac or normal. The first set of experiments was done to determine: a) mucosal immunoreactivity for (α-MSH and its

5   receptors and b) gene expression of α-MSH precursor pro-opiomelanocortin (POMC) and MCRs. The second series of biopsy pairs were used to determine: a) production of α-MSH peptide and cytokines by duodenal mucosa specimens incubated for 24 h *in vitro* and b) influence of synthetic α-MSH on cytokine production. Finally, specimen pairs were used to investigate: a) influence of gliadin-stimulation on α-MSH and cytokine

10   production *in vitro*, and b) effect of α-MSH on gliadin-stimulated cytokine production by duodenal mucosa.

[0053]   Thirty-four untreated patients with celiac disease (24-55 yr, 20 F) and 19 celiac patients on a gluten-free diet (25-52 yr, 11 F) undergoing upper duodenal endoscopy were included in this research. Diagnosis was made on the basis of positive

15   serologic tests (IgA-antiendomysial antibodies, IgG- and IgA-antigliadin antibodies), small bowel histology, clinical and histologic response to a gluten-free diet, and relapse following gluten challenge. Specimens from 14 subjects (26-66 yr, 6 F) investigated for gastrointestinal symptoms in whom endoscopic and histological findings were normal were used as controls.

20   [0054]   Four biopsy specimens from the distal duodenum were obtained during upper gastrointestinal endoscopy. Two of such specimens were fixed in 10% formalin

and paraffin embedded for standard histological examination. The remaining two

specimens from each subject were available for this research and were allocated for either

1) RT-PCR and immunohistochemical studies (N=20: 9 celiac, 7 celiac on diet, 4

normal); 2) cytokine production *in vitro* in the presence or absence of α-MSH (N=22: 11

5   celiac, 6 celiac on diet, 5 normal); or 3) cytokine production *in vitro* after gliadin

stimulation in the presence or absence of α-MSH (N=25: 14 celiac, 6 celiac on diet, 5

normal).

[0055]   Blood samples (7 ml in ethylenediamine tetra-acetic acid) were drawn from

an antecubital vein from all subjects for determination of circulating α-MSH. The

10   samples were immediately centrifuged and aliquots of plasma were stored at -80°C.

POMC and MCR gene expression

[0056]   Biopsy specimens of duodenal mucosa assigned to RT-PCR studies were

snap frozen in liquid nitrogen and stored at -80°C. Total RNA was isolated from

homogenized specimens using the acid phenol - guanidinium thiocyanate method

15   (Chomczynski P, Sacchi N., *Single-step method of RNA isolation by acid guanidinium*

thiocyanate-phenol -chloroform extraction, Anal Biochem 1987; 162:156-159), and

stored at -80°C. To prevent misinterpretation due to genomic contamination, as MCR

genes lack introns, total RNA was treated with amplification grade RNase-free DNase I

(Life Technologies, Gaithersburg, MD) at room temperature for 15 min. DNase I was

20   then inactivated by adding 2.5 mM EDTA and heating at 65°C for 10 min. First-strand

cDNA synthesis was performed, using 1 μg of each RNA sample, 20 pmoles of oligo

$(dT)^{18}$ primer, and 200 U of MMLV reverse transcriptase (Clontech Laboratories, Palo

Alto, CA) in a 20-µl reaction volume. PCR amplifications were performed on portions

(4-10%) of each diluted (1:5) cDNA mixture in a 25-µl reaction volume containing 20

pmoles each of upstream and downstream primers, 1U of AmpliTaq DNA polymerase

5   (Perkin Elmer Applied Biosystems, Foster City, CA), 200 µM dNTPs and 1-1.5 mM

$MgCl_2$. PCR reaction mixture and temperature profile conditions were tested against

positive controls for each specific mRNA in preliminary experiments. The POMC primer

pair (upstream 5'-GAGGGCAAGCGCTCCTACTCC-3', downstream 5'-

GGGGCCCTCGTCCTTCTTCTC-3') generated a 260-base pair (bp) product, the MCIR

10   pair (upstream 5'-GCCACCATCGCCAAGAACC-3', downstream 5'-

ATAGCCAGGAAGAAGACCA-3') a 416-bp product, the MC3R pair (upstream 5'-

CGGTGGCCGACATGCTGGTAAGTG-3', downstream 5'-

TGAGGAGCATCATGGCGAAGAACA -3') a 461-bp product, the MC5R pair

(upstream 5'-CATTGCTGTGGAGGTGTTTCT-3', downstream 5'-

15   GCCGTCATGATGTGGTGGTAG-3') a 357-bp product. All PCR products were

resolved by 2% agarose gel electrophoresis. A glyceraldehyde-3-phosphate

dehydrogenase (G3PDH) primer pair (upstream 5'-

TGAAGGTCGGAGTCAACGGATTTGGT-3', downstream 5'-

CATGTGGGCCATGAGGTCCACCAC-3'), generating a 980-bp product, was used for

20   normalization.

Immunohistochemistry

[0057]   Duodenal specimens assigned to immunohistochemical analysis were fixed in 10% buffered formalin and paraffin-embedded. Tissue sections (3 μm) were cut from paraffin-embedded blocks. Prior to use, sections were dewaxed, hydrated and

5   endogenous peroxidase activity was blocked by incubation with 1% hydrogen peroxide in distilled water. After antigen retrieval using microwave irradiation at 780 W in pH 6.0 citrate buffer for 15 min for, the slides were allowed to cool at room temperature for 20 min and incubated at 4°C overnight either with a rabbit polyclonal antibody against α-MSH (Eurodiagnostica, Malmö, Sweden) using a 1:600 dilution, or with goat polyclonal

10   antibodies against MC1R (1:400), MC3R (1:200), or MC5R (1:700) (Santa Cruz Biotechnology, Santa Cruz, CA). Sections were subsequently rinsed in Tris-NaCl buffer pH 7.6 and incubated at room temperature for 30 min with biotin-conjugated donkey anti-rabbit or donkey anti-goat IgG secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). After rinsing in Tris-NaCl buffer, sections were incubated for 30 min with

15   avidin-biotinylated horseradish peroxidase complex. The final reaction was run by incubating the sections in 0.002% 3'3'-diaminobenzidine (DAB) solution added with 0.01% hydrogen peroxide for 5 min. The sections were then washed in deionized H_2O and counterstained with Harry's hematoxylin.

α-MSH and cytokine production by celiac mucosa in vitro

20   [0058]   A series of 47 specimen pairs were used to evaluate cytokine production by celiac mucosa *in vitro* and the influence of α-MSH on such production. Twenty-two pairs

were used to evaluate spontaneous production and 25 were stimulated with gliadin; both

experiments were performed in the presence or absence of α-MSH. The duodenal

specimens were immediately placed in a 6-well culture plate and incubated in 5% CO_2

atmosphere at 37°C for 24 h with either 1) 1.5 ml medium (RPMI 1640 supplemented

5   with 10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES buffer), 50 U/ml

penicillin, 50 [μg/ml streptomycin or 2) medium and (α-MSH 10^{-5} M (kindly provided by

Dr. Renato Longhi, CNR, Milano) in the same final volume. To estimate the influence of

α-MSH on gliadin-stimulated cytokine production, each of the two specimens from the

same subject were incubated in the experimental conditions described above with either

10   1) peptic/tryptic digest of commercial gliadin (Sigma-Aldrich, St. Louis, MO) or 2)

gliadin and synthetic α-MSH 10^{-5} M. After 24 h incubation, the culture medium was

removed, distributed in 4 aliquots and stored at -80°C for measurement of interleukin 1β

(IL-1β), IL-6, and TNF-α. One of the aliquots from biopsies not treated with α-MSH

(medium alone or gliadin-stimulated) was used to measure endogenous production of α-

15   MSH by duodenal mucosa.

Assays

[0059]   α-MSH was measured using a double-antibody radioimmunoassay (RIA)

method (Eurodiagnostica, Malmö, Sweden); the sensitivity calculated from a decrease in

binding of 2 SD in the zero standard was 4.8 pg/ml and the cross-reactivity with other

20   POMC peptides (ACTH [1-24], ACTH [1-39], β-MSH, γ-MSH) is <0.002%. IL-1β, IL-6,

and TNF-α were determined using commercial ELISA methods (Amersham Pharmacia

Biotech, Little Chalfont, UK).

Statistical analysis

[0060]   Values were expressed as means ± SEM. Two-sample comparisons were

5   performed using Student's *t* test. Multiple comparisons were performed using analysis of

variance (ANOVA) followed by Bonferroni *t* test for specific comparisons (SigmaStat

Statistical Software, Jandel GmbH, Erkrath, Germany). Probability values < 0.05 were

considered significant.

α-MSH production by celiac mucosa in vitro

10   **[0061]**   Supernatants of duodenal mucosa incubated for 24 h *in vitro* showed a

small but clearly detectable spontaneous production of α-MSH, which was significantly

greater (p<0.05) in celiac patients (n=11) relative to both normal subjects (n=5) and

treated celiac patients (n=6) (Fig. 1). Conversely, such production was similar in normal

controls and treated celiac patients. When mucosal specimens were incubated with

15   gliadin for 24 h, mean α-MSH release was enhanced only in patients with untreated celiac

disease (Fig. 1) (p<0.05). The low production of peptide observed in normal duodenal

mucosa or in treated celiac patients was not altered by gliadin.

[0062]   α-MSH immunoreactive cells were present in duodenal mucosa specimens

of untreated celiac patients (Fig. 2). Immunoreactivity was mainly localized in

20   endocrine-like cells, although scattered cells in the lamina propria were likewise

immunoreactive. A few immunoreactive cells were occasionally found also in normal

duodenal specimens and in treated celiac patients (not shown).

[0063]   Presence of immunoreactive α-MSH was confirmed by expression of

mRNA for the α-MSH precursor POMC in duodenal mucosa homogenates (Fig. 3A).

5   [0064]   Plasma concentration of α-MSH in celiac patients was within the normal

range, although untreated patients had slightly higher concentrations relative to the other

two groups (20.46 ± 3.0, 28.4 ± 5.5, 22.35 ± 2.6, in normal, untreated celiac and treated

celiac respectively, $p > 0.05$).

MCRs expression in duodenal mucosa

10   [0065]   Immunohistochemical analysis of duodenal specimens for MC1R showed

positive staining of goblet cells in both celiac and normal subjects. However, the number

and distribution pattern of positive cells in non-celiac and celiac individuals was

substantially different. In non-celiac mucosa, MC1R immunoreactive cells were fewer

and localized solely to the base of glands (Figs. 4A, 4B). Immunostaining occurred

15   mainly in the outer margins of the mucous globule. No immunoreactivity was found on

the villous surface in normal mucosa. In celiac mucosa, the majority of goblet cells were

immunoreactive for MC1R; such cells were distributed along the entire length of

glandular tubules and on the surface of flattened villi (Figs. 4C, 4D). Further, there was a

substantial difference in intensity of immunostaining; it was stronger in cells of celiac

20   mucosa and much weaker in goblet cells of non-celiac mucosa. MC1R immunoreactivity

in celiac patients treated with a gluten-free diet showed the same pattern of distribution

observed in patients with active disease, involving the villous surface but with less

intensity of immunostaining (Figs. 4E, 4F).

[0066]   Scattered cells showed staining with the antiserum against MC5R. Such

cells were distributed in both glandular crypts and mucosal villi; the pattern of

5   immunostaining was similar to that usually shown by neuroendocrine cells, being more

evident in the subnuclear area of the cytoplasm (Fig. 5). There was no substantial

difference between specimens from celiac and control subjects.

[0067]   Presence of MC1R in duodenal mucosa was confirmed by expression of

mRNA for this receptor subtype (Fig. 3B). No mRNA for MC5R was found. This is not

10   surprising since there were very few immunoreactive cells. No expression of the receptor

subtype MC3R was found using either immunohistochemical or RT-PCR techniques.

Influence of α-MSH on cytokine production in vitro

[0068]   Non-stimulated 24 h production of IL-1β, IL-6, and TNF- α by celiac

mucosa *in vitro* was low or undetectable and there was no change after addition of α-

15   MSH to the incubation medium.

[0069]   Twenty-four hour incubation of duodenal specimens *in vitro* with gliadin

significantly enhanced IL-6 release in the supernatants (Fig. 6). Concentration of the

cytokine in presence of gliadin was significantly greater in celiac patients relative to

patients with inactive disease or controls (n= 5 controls, 14 untreated celiac, and 6 treated

20   celiac patients). When gliadin-stimulated duodenal specimens were co-incubated with α-

MSH, there was a statistically significant inhibition of IL-6 release in all groups. IL-1β

and TNF-α were low or undetectable even after gliadin stimulation in all groups (not shown).

[0070]   From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various

5   modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims. The preceding Examples are intended only as examples and are not intended to limit the invention. It is understood that modifying the examples above does not depart from the spirit of the invention. It is further understood that the each example may be applied on

10   its own or in combination with other examples.